Getting to know ovarian cancer ascites: opportunities for targeted therapy-based translational research
N Ahmed, KL Stenvers - Frontiers in oncology, 2013 - frontiersin.org
More than one third of ovarian cancer patients present with ascites at diagnosis, and almost
all have ascites at recurrence. The presence of ascites correlates with the peritoneal spread …
all have ascites at recurrence. The presence of ascites correlates with the peritoneal spread …
Malignant ascites in ovarian cancer: cellular, acellular, and biophysical determinants of molecular characteristics and therapy response
Simple Summary Accumulation of excess fluid in the abdomen typically indicates abnormal
function or disease, such as cancer, in the underlying tissues. This accumulation of fluid, or …
function or disease, such as cancer, in the underlying tissues. This accumulation of fluid, or …
Cytokine patterns in cancer patients: A review of the correlation between interleukin 6 and prognosis
BE Lippitz, RA Harris - Oncoimmunology, 2016 - Taylor & Francis
Objective: In tumor patients, IL-6 appears to be one component of a consistent cancer-
associated cytokine network resulting in both a systemic immune stimulation and a …
associated cytokine network resulting in both a systemic immune stimulation and a …
Assessment and management of cancer-related fatigue in adults
K Ahlberg, T Ekman, F Gaston-Johansson, V Mock - The lancet, 2003 - thelancet.com
Fatigue is one of the most prevalent and distressing symptoms of cancer, and is a common
side-effect of many of the treatments available for the management of malignant disease. We …
side-effect of many of the treatments available for the management of malignant disease. We …
The role of inflammation and inflammatory mediators in the development, progression, metastasis, and chemoresistance of epithelial ovarian cancer
SS Savant, S Sriramkumar, HM O'Hagan - Cancers, 2018 - mdpi.com
Inflammation plays a role in the initiation and development of many types of cancers,
including epithelial ovarian cancer (EOC) and high grade serous ovarian cancer (HGSC), a …
including epithelial ovarian cancer (EOC) and high grade serous ovarian cancer (HGSC), a …
Mechanisms of transcoelomic metastasis in ovarian cancer
DSP Tan, R Agarwal, SB Kaye - The lancet oncology, 2006 - thelancet.com
Metastasis from epithelial ovarian cancer can occur via the transcoelomic,
haematogeneous, or lymphatic route. Of these, transcoelomic metastasis is the most …
haematogeneous, or lymphatic route. Of these, transcoelomic metastasis is the most …
Circulating interleukin‐6 predicts survival in patients with metastatic breast cancer
R Salgado, S Junius, I Benoy… - … journal of cancer, 2003 - Wiley Online Library
Abstract Interleukin‐6 (IL‐6) is a multifunctional cytokine produced by macrophages, T cells,
B cells, endothelial cells and tumour cells. Interleukin‐6 is able to promote tumour growth by …
B cells, endothelial cells and tumour cells. Interleukin‐6 is able to promote tumour growth by …
Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: a review of the rationale and clinical evidence
M Trikha, R Corringham, B Klein, JF Rossi - Clinical cancer research, 2003 - AACR
Abstract Interleukin (IL)-6, a pleiotropic cytokine with varied systemic functions, plays a major
role in inflammatory processes. It modulates the transcription of several liver-specific genes …
role in inflammatory processes. It modulates the transcription of several liver-specific genes …
Development of a multimarker assay for early detection of ovarian cancer
Z Yurkovetsky, S Skates, A Lomakin, B Nolen… - Journal of Clinical …, 2010 - ascopubs.org
Purpose Early detection of ovarian cancer has great promise to improve clinical outcome.
Patients and Methods Ninety-six serum biomarkers were analyzed in sera from healthy …
Patients and Methods Ninety-six serum biomarkers were analyzed in sera from healthy …
Interleukin-6, secreted by human ovarian carcinoma cells, is a potent proangiogenic cytokine
MB Nilsson, RR Langley, IJ Fidler - Cancer research, 2005 - AACR
Angiogenesis, a key rate-limiting step in the growth and dissemination of malignant tumors,
is regulated by the balance between positive and negative effectors. Recent studies indicate …
is regulated by the balance between positive and negative effectors. Recent studies indicate …